See more : ClearSign Technologies Corporation (CLIR) Income Statement Analysis – Financial Results
Complete financial analysis of Enzolytics Inc. (ENZC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Enzolytics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Kuen Ling Machinery Refrigerating Co., Ltd. (4527.TWO) Income Statement Analysis – Financial Results
- Atomera Incorporated (ATOM) Income Statement Analysis – Financial Results
- TOWA Corporation (6315.T) Income Statement Analysis – Financial Results
- China Communications Services Corporation Limited (0552.HK) Income Statement Analysis – Financial Results
- Alpine Acquisition Corporation (REVE) Income Statement Analysis – Financial Results
Enzolytics Inc. (ENZC)
About Enzolytics Inc.
Enzolytics, Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, it has created a proprietary cell line that produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is based in Plano, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 52.80K | 0.00 | 200.00K | 0.00 | 0.00 | 5.00K | 190.00K | 0.00 | 0.00 | 36.97K | 14.71K | 5.69K | 0.00 |
| Cost of Revenue | 22.09K | 22.09K | 16.96K | 16.96K | 16.96K | 16.81K | 741.20K | 18.75K | 19.22K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 30.71K | -22.09K | 183.04K | -16.96K | -16.96K | -11.81K | -551.20K | -18.75K | -19.22K | 36.97K | 14.71K | 5.69K | 0.00 |
| Gross Profit Ratio | 58.16% | 0.00% | 91.52% | 0.00% | 0.00% | -236.20% | -290.10% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 171.61K | 567.87K | 116.75K | 501.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.90M | 936.82K | 394.12K | 40.20K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.01M | 2.31M | 1.47M | 2.78M | 645.41K | 1.69M | 264.81K | 45.29K | 5.02M | 2.90M | 936.82K | 394.12K | 40.20K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.29M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 2.18M | 2.88M | 1.59M | 3.29M | 645.41K | 1.69M | 264.81K | 45.29K | 5.02M | 2.91M | 950.12K | 403.00K | 43.18K |
| Cost & Expenses | 2.20M | 2.90M | 1.61M | 3.30M | 662.37K | 1.71M | 1.01M | 64.04K | 5.04M | 2.91M | 950.12K | 403.00K | 43.18K |
| Interest Income | 2.00 | 60.00 | 91.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 27.72K | 37.32K | 37.33K | 177.30K | 118.82K | 50.99K | 61.73K | 21.92K | 24.62K | 68.95K | 34.38K | 28.64K | 21.64K |
| Depreciation & Amortization | 22.09K | 22.09K | 20.44K | 16.96K | 16.96K | 16.81K | 322.99K | 18.75K | 19.22K | 12.38K | 13.30K | 8.87K | 2.98K |
| EBITDA | -2.12M | -2.88M | -611.72K | -3.29M | 1.06M | -1.69M | 327.44K | -45.29K | -5.02M | -7.43M | -922.12K | -388.44K | 316.60K |
| EBITDA Ratio | -4,019.30% | 0.00% | -695.19% | 0.00% | 0.00% | -33,798.60% | -259.48% | 0.00% | 0.00% | -16,649.25% | -6,269.48% | -6,830.26% | 0.00% |
| Operating Income | -2.15M | -2.90M | -1.41M | -3.30M | -662.37K | -1.71M | -816.01K | -64.04K | -5.04M | -2.88M | -935.41K | -397.31K | -43.18K |
| Operating Income Ratio | -4,070.01% | 0.00% | -705.41% | 0.00% | 0.00% | -34,134.80% | -429.48% | 0.00% | 0.00% | -7,777.15% | -6,359.89% | -6,986.30% | 0.00% |
| Total Other Income/Expenses | -28.03K | -37.26K | 741.33K | -177.30K | 1.58M | -50.99K | 758.73K | -489.33K | -24.62K | -4.64M | -34.38K | -28.64K | -356.80K |
| Income Before Tax | -2.18M | -2.94M | -669.49K | -3.48M | 920.43K | -1.76M | -57.28K | -553.37K | -5.07M | -7.51M | -969.79K | 0.00 | -399.98K |
| Income Before Tax Ratio | -4,123.10% | 0.00% | -334.74% | 0.00% | 0.00% | -35,154.52% | -30.15% | 0.00% | 0.00% | -20,325.46% | -6,593.61% | 0.00% | 0.00% |
| Income Tax Expense | 2.00 | 2.00 | -2.00 | -4.00 | -4.00 | 0.00 | -4.00 | -3.78K | -19.28K | -3.22M | 0.00 | 28.64K | 378.44K |
| Net Income | -2.18M | -2.94M | -669.49K | -3.48M | 920.43K | -1.76M | -57.28K | -549.59K | -5.05M | -7.51M | -969.79K | -425.95K | -421.62K |
| Net Income Ratio | -4,123.10% | 0.00% | -334.74% | 0.00% | 0.00% | -35,154.52% | -30.15% | 0.00% | 0.00% | -20,325.46% | -6,593.61% | -7,489.85% | 0.00% |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.04 | -541.66 | -256.63 | -118.91 | -155.29 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.04 | -541.66 | -256.63 | -118.91 | -155.29 |
| Weighted Avg Shares Out | 2.93B | 2.82B | 2.80B | 959.33M | 959.33M | 391.52M | 171.67M | 110.79M | 114.79M | 13.87K | 3.78K | 3.58K | 2.72K |
| Weighted Avg Shares Out (Dil) | 2.93B | 2.82B | 2.80B | 959.33M | 959.33M | 391.52M | 171.67M | 110.79M | 114.79M | 13.87K | 3.78K | 3.58K | 2.72K |
CORRECTION FROM SOURCE: Virogentics Announces Approval of Final Protocol from the Dept for HIV and AIDS, Ministry of Health of the DRC
Expects to Issue Update on EMA Progress ALLEN, TX / ACCESSWIRE / July 24, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). CORRECTED Virogentics, Inc. ("VIRO") a wholly owned subsidiary of Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech...
Virogentics, Inc to Introduce a Dietary Supplement Offers Additional Information on ITV-1 and Diabetic Clinical Trials
ALLEN, TX / ACCESSWIRE / July 24, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). Virogentics, Inc. ("VIRO") a wholly owned subsidiary of Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, announced today it has received approval of...
Biogenysis Inc. Announces a Collaboration with Khalpey AI Lab in using Artificial Intelligence (AI) for Unveiling Potential Biomarkers and Predicting the Onset or Prevention of Alzheimer's Disease.
COLLEGE STATION, TX / ACCESSWIRE / July 21, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). Biogenysis, Inc. ("BGEN"), a wholly owned subsidiary of Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, announced today a partnership with Khalpey...
Enzolytics Inc. Files Supplemental Information Report on the Sale of Biogenysis, Inc. and Virogentics, Inc to Sagaliam Acquisition Corp.
COLLEGE STATION, TX / ACCESSWIRE / July 11, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). Enzolytics, Inc. ("ENZC" or the "Company") filed a Supplemental Information report today to provide additional details regarding the recently entered non-binding letter of intent with...
Hot Penny Stocks to Watch in the First Full Week of December
Check these three penny stocks out for your watchlist this week The post Hot Penny Stocks to Watch in the First Full Week of December appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Are These Penny Stocks on Your Late-November Watchlist?
Here's three penny stocks for your end of November watchlist The post Are These Penny Stocks on Your Late-November Watchlist? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
3 Trending Penny Stocks to Watch As Bitcoin Surges In October 2021
Looking for trending penny stocks to watch right now, check these three out in October The post 3 Trending Penny Stocks to Watch As Bitcoin Surges In October 2021 appeared first on Penny Stocks to Buy, Picks, News and Information...
5 Penny Stocks Under $1 To Watch Before October 2021
5 penny stocks to watch & they're all under $1 right now. The post 5 Penny Stocks Under $1 To Watch Before October 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
5 Penny Stocks To Watch Under $1 After CEI Stock's 900% Rally
Best penny stocks to watch under $1? The post 5 Penny Stocks To Watch Under $1 After CEI Stock's 900% Rally appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Do These Penny Stocks Present a Buying Opportunity At Current Prices?
Are these penny stocks worth buying at their current level? Take a look and find out The post Do These Penny Stocks Present a Buying Opportunity At Current Prices?
Source: https://incomestatements.info
Category: Stock Reports